Samsung Bioepis’ Pembrolizumab biosimilar SB27 meets phase 1 PK endpoints
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Subscribe To Our Newsletter & Stay Updated